Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis

ConclusionSSA impaired the insulin, glucagon, and incretin hormone secretions. Co-treatment with PEG seemed to counteract the somatostatinergic inhibition of the glucagon and insulin response to OGTT. We speculate that PEG may exert its action through GH-receptors on pancreatic δ-cells.Clinical trial registration NCT02005978.

Source: Pituitary - January 6, 2023 Category: Endocrinology Source Type: research